{"name":"Amgen","permalink":"amgen","crunchbase_url":"http://www.crunchbase.com/company/amgen","homepage_url":"http://www.amgen.com","blog_url":"","blog_feed_url":"","twitter_username":"","category_code":"biotech","number_of_employees":null,"founded_year":1985,"founded_month":null,"founded_day":null,"deadpooled_year":null,"deadpooled_month":null,"deadpooled_day":null,"deadpooled_url":null,"tag_list":null,"alias_list":"","email_address":"","phone_number":"+1 805-447-1000","description":"biotechnology company","created_at":"Wed May 20 17:00:19 UTC 2009","updated_at":"Wed Apr 11 01:50:45 UTC 2012","overview":"<p>Amgen Inc.. The Group&#8217;s principal activities are to discover, develop, manufacture and market human therapeutics based on advances in cellular and molecular biology. It markets human therapeutic products in the areas of hematology, oncology and inflammation. The Group&#8217;s key products include Aranesp(R) (darbepoetin alfa), EPOGEN(R) (Epoetin alfa), Neulasta(R) (pegfilgrastim), NEUPOGEN(R) (Filgrastim) and Enbrel(R) (etanercept) stimulate the production of red blood cells, for the treatment of anemia associated with chronic renal failure. Neulasta(R) and NEUPOGEN(R) selectively stimulate the production of neutrophils, one type of white blood cell, for treatment of infection in-patients undergoing myelosuppressive chemotherapy. ENBREL(R) blocks the biologic activity of tumor necrosis factor, which is used for treating patients with active rheumatoid arthritis</p>","image":{"available_sizes":[[[97,28],"assets/images/resized/0005/9904/59904v1-max-150x150.jpg"],[[97,28],"assets/images/resized/0005/9904/59904v1-max-250x250.jpg"],[[97,28],"assets/images/resized/0005/9904/59904v1-max-450x450.jpg"]],"attribution":null},"products":[],"relationships":[{"is_past":false,"title":"","person":{"first_name":"Anne","last_name":"Dixon","permalink":"anne-m-dixon","image":{"available_sizes":[[[106,150],"assets/images/resized/0006/1179/61179v2-max-150x150.jpg"],[[120,169],"assets/images/resized/0006/1179/61179v2-max-250x250.jpg"],[[120,169],"assets/images/resized/0006/1179/61179v2-max-450x450.jpg"]],"attribution":"<p>Oulixeus Ltd.</p>"}}},{"is_past":false,"title":"Business Planning Analyst","person":{"first_name":"Joe","last_name":"Sandoval","permalink":"joe-sandoval-2","image":null}},{"is_past":true,"title":"Technology Consultant","person":{"first_name":"Mooky","last_name":"Desai","permalink":"mooky-desai","image":{"available_sizes":[[[150,112],"assets/images/resized/0004/4830/44830v2-max-150x150.jpg"],[[250,187],"assets/images/resized/0004/4830/44830v2-max-250x250.jpg"],[[450,338],"assets/images/resized/0004/4830/44830v2-max-450x450.jpg"]],"attribution":""}}},{"is_past":true,"title":"","person":{"first_name":"Jim","last_name":"Haughwout","permalink":"jim-haughwout","image":{"available_sizes":[[[144,147],"assets/images/resized/0003/3607/33607v6-max-150x150.png"],[[144,147],"assets/images/resized/0003/3607/33607v6-max-250x250.png"],[[144,147],"assets/images/resized/0003/3607/33607v6-max-450x450.png"]],"attribution":"<p>Bill Coletti</p>"}}}],"competitions":[],"providerships":[{"title":"","is_past":false,"provider":{"name":"Cooley ","permalink":"cooley-godward-kronish-llp","image":{"available_sizes":[[[150,54],"assets/images/resized/0009/4482/94482v2-max-150x150.jpg"],[[250,90],"assets/images/resized/0009/4482/94482v2-max-250x250.jpg"],[[429,155],"assets/images/resized/0009/4482/94482v2-max-450x450.jpg"]],"attribution":null}}}],"total_money_raised":"$0","funding_rounds":[],"investments":[{"funding_round":{"round_code":"e","source_url":"http://www.finsmes.com/2012/05/gamida-cell-closes-10m-series-financing.html?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+finsmes%2FcNHu+%28FinSMEs%29","source_description":"Gamida Cell Closes $10m Series E Financing","raised_amount":10000000,"raised_currency_code":"USD","funded_year":2012,"funded_month":5,"funded_day":15,"company":{"name":"Gamida Cell","permalink":"gamida-cell","image":{"available_sizes":[[[150,47],"assets/images/resized/0008/4575/84575v1-max-150x150.jpg"],[[194,61],"assets/images/resized/0008/4575/84575v1-max-250x250.jpg"],[[194,61],"assets/images/resized/0008/4575/84575v1-max-450x450.jpg"]],"attribution":null}}}}],"acquisition":null,"acquisitions":[{"price_amount":380000000,"price_currency_code":"USD","term_code":"cash","source_url":"http://deals.venturebeat.com/2006/10/02/amgen-to-buy-inflammation-drug-co-avidia-for-up-to-380m/","source_description":"Amgen to buy inflammation drug co. Avidia for up to $380M","acquired_year":2008,"acquired_month":10,"acquired_day":2,"company":{"name":"Avidia","permalink":"avidia","image":null}},{"price_amount":420000000,"price_currency_code":"USD","term_code":"cash","source_url":"http://venturebeat.com/2007/06/05/amgen-buys-kidney-disease-biotech-ilypsa-for-420m/","source_description":"Amgen buys kidney-disease biotech Ilypsa for $420M","acquired_year":2007,"acquired_month":6,"acquired_day":5,"company":{"name":"Ilypsa","permalink":"ilypsa","image":null}},{"price_amount":1000000000,"price_currency_code":"USD","term_code":"cash","source_url":"http://www.masshightech.com/stories/2011/01/24/daily17-BioVex-to-be-acquired-by-Amgen-for-up-to-1-billion.html","source_description":"BioVex to be acquired by Amgen for up to $1 billion","acquired_year":2011,"acquired_month":1,"acquired_day":25,"company":{"name":"BioVex","permalink":"biovex","image":{"available_sizes":[[[150,40],"assets/images/resized/0004/9487/49487v2-max-150x150.jpg"],[[250,68],"assets/images/resized/0004/9487/49487v2-max-250x250.jpg"],[[294,80],"assets/images/resized/0004/9487/49487v2-max-450x450.jpg"]],"attribution":null}}},{"price_amount":315000000,"price_currency_code":"USD","term_code":"cash","source_url":"http://www.fiercebiotech.com/story/amgen-snags-kai-pharmas-ckd-program-315m-buyout/2012-04-10","source_description":"UPDATED: Amgen snags KAI Pharma's CKD program in $315M buyout ","acquired_year":2012,"acquired_month":4,"acquired_day":10,"company":{"name":"KAI Pharmaceuticals","permalink":"kai-pharmaceuticals","image":{"available_sizes":[[[150,45],"assets/images/resized/0008/4290/84290v1-max-150x150.jpg"],[[247,75],"assets/images/resized/0008/4290/84290v1-max-250x250.jpg"],[[247,75],"assets/images/resized/0008/4290/84290v1-max-450x450.jpg"]],"attribution":null}}}],"offices":[{"description":"HQ","address1":"One Amgen Center Drive","address2":"","zip_code":"91320-1799","city":"Thousand Oaks","state_code":"CA","country_code":"USA","latitude":null,"longitude":null}],"milestones":[{"description":"Amgen pays Nektar $50M for polymer","stoned_year":2010,"stoned_month":11,"stoned_day":2,"source_url":"http://www.fiercebiotech.com/story/amgen-pays-nektar-50m-polymer/2010-11-02?utm_medium=rss&utm_source=rss","source_text":"","source_description":"Amgen pays Nektar $50M for polymer","stoneable_type":"Company","stoned_value":null,"stoned_value_type":null,"stoned_acquirer":null,"stoneable":{"name":"Amgen","permalink":"amgen"}},{"description":"Amgen, has reached agreement to acquire BioVex Group Inc. for what could total $1 billion","stoned_year":2011,"stoned_month":1,"stoned_day":25,"source_url":"http://www.masshightech.com/stories/2011/01/24/daily17-BioVex-to-be-acquired-by-Amgen-for-up-to-1-billion.html","source_text":null,"source_description":"BioVex to be acquired by Amgen for up to $1 billion","stoneable_type":"Company","stoned_value":null,"stoned_value_type":null,"stoned_acquirer":null,"stoneable":{"name":"Amgen","permalink":"amgen"}}],"ipo":null,"video_embeds":[],"screenshots":[{"available_sizes":[[[150,132],"assets/images/resized/0005/9905/59905v1-max-150x150.jpg"],[[250,221],"assets/images/resized/0005/9905/59905v1-max-250x250.jpg"],[[450,398],"assets/images/resized/0005/9905/59905v1-max-450x450.jpg"]],"attribution":null}],"external_links":[]}